PMID- 36680771
OWN - NLM
STAT- MEDLINE
DCOM- 20230410
LR  - 20230410
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 75
IP  - 4
DP  - 2023 Apr 7
TI  - Sophorolipids produced by Yarrowia lipolytica grown on Moringa oleifera oil cake 
      protect against acetic acid-induced colitis in rats: impact on 
      TLR-4/p-JNK/NFkappaB-p65 pathway.
PG  - 544-558
LID - 10.1093/jpp/rgac101 [doi]
AB  - OBJECTIVES: Toll-like receptor-4 (TLR-4) activation plays a major role in 
      triggering oxidative stress (OS) and inflammation implicated in the pathogenesis 
      of ulcerative colitis (UC). Due to sophorolipids (SLs) antioxidant and 
      anti-inflammatory properties, they are interestingly becoming more valued for 
      their potential effectiveness in treating a variety of diseases. This study was 
      designed to explore the effect of SLs produced by microbial conversion of Moringa 
      oleifera oil cake using isolated yeast Yarrowia lipolytica against UC induced by 
      acetic acid (AA) in rats. METHODS: The produced SLs were identified by FTIR, 1H 
      NMR and LC-MS/MS spectra, and administered orally for 7 days (200 mg/kg/day) 
      before AA (2 ml, 4% v/v) to induce UC intrarectally on day eight. Biochemically, 
      the levels of TLR-4, c-Jun N-terminal kinase (JNK), nuclear factor kappa B-p65 
      (NFkappaB-p65), interleukin-1beta (IL-1beta), malondialdehyd, glutathione, Bax/Bcl2 
      ratio and the immunohistochemical evaluation of inducible nitric oxide synthase 
      and caspase-3 were assayed. KEY FINDINGS: SLs significantly reduced OS, 
      inflammatory and apoptotic markers in AA-treated rats, almost like the reference 
      sulfasalazine. CONCLUSIONS: This study provided a novel impact for SLs produced 
      by microbial conversion of M. oleifera oil cake against AA-induced UC in rats 
      through hampering the TLR-4/p-JNK/NFkappaB-p65 signalling pathway.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the Royal 
      Pharmaceutical Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Nooman, Mohamed U
AU  - Nooman MU
AD  - Biochemistry Department, Biotechnology Research Institute, National Research 
      Centre, Cairo, Egypt.
FAU - Al-Kashef, Amr S
AU  - Al-Kashef AS
AD  - Biochemistry Department, Biotechnology Research Institute, National Research 
      Centre, Cairo, Egypt.
FAU - Rashad, Mona M
AU  - Rashad MM
AD  - Biochemistry Department, Biotechnology Research Institute, National Research 
      Centre, Cairo, Egypt.
FAU - Khattab, Abd El-Nasser A
AU  - Khattab AEA
AD  - Genetics and Cytology Department, Biotechnology Research Institute, National 
      Research Centre, Cairo, Egypt.
FAU - Ahmed, Kawkab A
AU  - Ahmed KA
AD  - Pathology Department, Faculty of Veterinary Medicine, Cairo University, Cairo, 
      Egypt.
FAU - Abbas, Samah S
AU  - Abbas SS
AUID- ORCID: 0000-0002-5324-838X
AD  - Pharmacology and Toxicology Department, Faculty of Pharmacy, Misr International 
      University, Cairo, Egypt.
LA  - eng
GR  - 20-111/National Research Centre/
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - Q40Q9N063P (Acetic Acid)
RN  - 0 (sophorolipid)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Acetic Acid/pharmacology
MH  - *Moringa oleifera
MH  - *Yarrowia/metabolism
MH  - Chromatography, Liquid
MH  - Toll-Like Receptor 4/metabolism
MH  - Rats, Wistar
MH  - Tandem Mass Spectrometry
MH  - *Colitis/pathology
MH  - *Colitis, Ulcerative/chemically induced/drug therapy/prevention & control
MH  - NF-kappa B/metabolism
MH  - Colon
OTO - NOTNLM
OT  - Moringa oleifera
OT  - Yarrowia lipolytica
OT  - NFkappaB-p65
OT  - Sophorolipids
OT  - TLR4
OT  - colitis
EDAT- 2023/01/22 06:00
MHDA- 2023/04/10 10:16
CRDT- 2023/01/21 12:32
PHST- 2022/08/12 00:00 [received]
PHST- 2022/12/14 00:00 [accepted]
PHST- 2023/04/10 10:16 [medline]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/21 12:32 [entrez]
AID - 6995397 [pii]
AID - 10.1093/jpp/rgac101 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2023 Apr 7;75(4):544-558. doi: 10.1093/jpp/rgac101.